Ep 183: Tom O'Halloran: Is It Time To Be Bullish Again?
Investing With IBD
Arusha Pharmaceuticals' Revenue Drops
Vivgard has the application for this ailment, but many other autoimmune disorders. The sales are exceeding expectations coming out of the gates. We're looking forward to other indications which would be additive to the new drug. And that will determine the future course of this drug. It's a really strong relative strength. So far, you know, the markets agreeing with Tom and his team.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
